Cargando…

Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia

BACKGROUND: Drug resistance and disease progression are still the major obstacles in the treatment of chronic myeloid leukemia (CML). Increasing researches have demonstrated that autophagy becomes activated when cancer cells are subjected to chemotherapy, which is involved in the development of drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ziyuan, Xu, Na, He, Bolin, Pan, Chengyun, Lan, Yangqing, Zhou, Hongsheng, Liu, Xiaoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345227/
https://www.ncbi.nlm.nih.gov/pubmed/28283035
http://dx.doi.org/10.1186/s13046-017-0512-6
_version_ 1782513674324279296
author Lu, Ziyuan
Xu, Na
He, Bolin
Pan, Chengyun
Lan, Yangqing
Zhou, Hongsheng
Liu, Xiaoli
author_facet Lu, Ziyuan
Xu, Na
He, Bolin
Pan, Chengyun
Lan, Yangqing
Zhou, Hongsheng
Liu, Xiaoli
author_sort Lu, Ziyuan
collection PubMed
description BACKGROUND: Drug resistance and disease progression are still the major obstacles in the treatment of chronic myeloid leukemia (CML). Increasing researches have demonstrated that autophagy becomes activated when cancer cells are subjected to chemotherapy, which is involved in the development of drug resistance. Therefore, combining chemotherapy with inhibition of autophagy serves as a new strategy in cancer treatment. Tigecycline is an antibiotic that has received attention as an anti-cancer agent due to its inhibitory effect on mitochondrial translation. However, whether combination of tigecycline with inhibition of autophagy could overcome drug resistance in CML remains unclear. METHODS: We analyzed the biological and metabolic effect of tigecycline on CML primary cells and cell lines to investigate whether tigecycline could regulate autophagy in CML cells and whether coupling autophagy inhibition with treatment using tigecycline could affect the viabilities of drug-sensitive and drug-resistant CML cells. RESULTS: Tigecycline inhibited the viabilities of CML primary cells and cell lines, including those that were drug-resistant. This occurred via the inhibition of mitochondrial biogenesis and the perturbation of cell metabolism, which resulted in apoptosis. Moreover, tigecycline induced autophagy by downregulating the PI3K-AKT-mTOR pathway. Additionally, combining tigecycline use with autophagy inhibition further promoted the anti-leukemic activity of tigecycline. We also observed that the anti-leukemic effect of tigecycline is selective. This is because the drug targeted leukemic cells but not normal cells, which is because of the differences in the mitochondrial biogenesis and metabolic characterization between the two cell types. CONCLUSIONS: Combining tigecycline use with autophagy inhibition is a promising approach for overcoming drug resistance in CML treatment.
format Online
Article
Text
id pubmed-5345227
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53452272017-03-14 Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia Lu, Ziyuan Xu, Na He, Bolin Pan, Chengyun Lan, Yangqing Zhou, Hongsheng Liu, Xiaoli J Exp Clin Cancer Res Research BACKGROUND: Drug resistance and disease progression are still the major obstacles in the treatment of chronic myeloid leukemia (CML). Increasing researches have demonstrated that autophagy becomes activated when cancer cells are subjected to chemotherapy, which is involved in the development of drug resistance. Therefore, combining chemotherapy with inhibition of autophagy serves as a new strategy in cancer treatment. Tigecycline is an antibiotic that has received attention as an anti-cancer agent due to its inhibitory effect on mitochondrial translation. However, whether combination of tigecycline with inhibition of autophagy could overcome drug resistance in CML remains unclear. METHODS: We analyzed the biological and metabolic effect of tigecycline on CML primary cells and cell lines to investigate whether tigecycline could regulate autophagy in CML cells and whether coupling autophagy inhibition with treatment using tigecycline could affect the viabilities of drug-sensitive and drug-resistant CML cells. RESULTS: Tigecycline inhibited the viabilities of CML primary cells and cell lines, including those that were drug-resistant. This occurred via the inhibition of mitochondrial biogenesis and the perturbation of cell metabolism, which resulted in apoptosis. Moreover, tigecycline induced autophagy by downregulating the PI3K-AKT-mTOR pathway. Additionally, combining tigecycline use with autophagy inhibition further promoted the anti-leukemic activity of tigecycline. We also observed that the anti-leukemic effect of tigecycline is selective. This is because the drug targeted leukemic cells but not normal cells, which is because of the differences in the mitochondrial biogenesis and metabolic characterization between the two cell types. CONCLUSIONS: Combining tigecycline use with autophagy inhibition is a promising approach for overcoming drug resistance in CML treatment. BioMed Central 2017-03-10 /pmc/articles/PMC5345227/ /pubmed/28283035 http://dx.doi.org/10.1186/s13046-017-0512-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lu, Ziyuan
Xu, Na
He, Bolin
Pan, Chengyun
Lan, Yangqing
Zhou, Hongsheng
Liu, Xiaoli
Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
title Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
title_full Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
title_fullStr Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
title_full_unstemmed Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
title_short Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
title_sort inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345227/
https://www.ncbi.nlm.nih.gov/pubmed/28283035
http://dx.doi.org/10.1186/s13046-017-0512-6
work_keys_str_mv AT luziyuan inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia
AT xuna inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia
AT hebolin inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia
AT panchengyun inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia
AT lanyangqing inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia
AT zhouhongsheng inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia
AT liuxiaoli inhibitionofautophagyenhancestheselectiveanticanceractivityoftigecyclinetoovercomedrugresistanceinthetreatmentofchronicmyeloidleukemia